First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) has a cure rate of approximately 60% with standard R-CHOP immunochemotherapy.
• The cyclic-AMP/phosphodiesterase 4 (PDE4) pathway is implicated in lymphomagenesis.
• Roflumilast, a PDE4 inhibitor, has demonstrated potential to inhibit B-cell receptor (BCR) signaling, phosphoinositide 3-kinase (PI3K) activity, and angiogenesis.

Purpose of the Study:

• To evaluate the safety and efficacy of combining roflumilast with R-CHOP in treatment-naïve, high-risk DLBCL patients.
• To explore the biological effects of roflumilast in combination with R-CHOP.
• To identify potential patient subgroups who may benefit most from this combination therapy.

Main Methods:

• A single-center, single-arm, open-label, phase 1 clinical trial was conducted.
• Roflumilast was administered in combination with standard R-CHOP chemotherapy.
• Patients with pathologically proven, treatment-naïve, high-risk DLBCL were enrolled.

Main Results:

• The combination of roflumilast and R-CHOP (Ro+R-CHOP) was found to be safe.
• At a median follow-up of 44 months, 70% of patients achieved event-free survival.
• Roflumilast suppressed PI3K activity and VEGF-A secretion, with preliminary evidence of benefit in high-risk genetic subtypes (MCD and A53).

Conclusions:

• Roflumilast shows potential as an agent to inhibit BCR/PI3K activity and angiogenesis in DLBCL.
• The Ro+R-CHOP combination warrants further investigation in a larger cohort of genetically characterized DLBCL tumors.
• This study provides a foundation for future clinical trials exploring novel therapeutic strategies for DLBCL.